a Original cataloging agency NEU GrandLibrary

a Language code of text/sound track or separate title eng

a Classification number WF 553

b Item number .T44 2014

a Personal name Yalçın, A.D.

h Medium Electronic Document

a Title There Might be a Risk of Anaphylaxis Due to Omalizumab (Anti-IgE) Therapy.

c Statement of responsibility, etc A.D. Yalcin, K. Suer. A.N. Yalcin.

c Date of publication, distribution, etc 2014.

a Summary, etc Omalizumab, a humanized mAb that binds to the CH3 domain, near the binding site for the high-affinity type-I IgE Fc receptors of human IgE, can neutralize free IgE and inhibit the IgE allergic pathway without sensitizing mast cell and basophils. The clinical experience during the patient follow-up of an omalizumab treated severe persistent allergic asthma patient with complicated viral infection is introduced. A female patient (aged 58) with severe persistent allergic asthma, on omalizumab therapy had laryngeal oedema during a complicated common cold infection with bacterial sinusitis after omalizumab injection. Systemic steroids, ketotifen fumarate, antibiotic and antihistamines (desloratadine) were given. We did not stop omalizumab therapy. To our knowledge, this is the first time an association between omalizumab use and laryngeal oedema has been documented. In fact we do not know the exact mechanism behind this relationship.

a Topical term or geographic name as entry element Near East University Article

a Topical term or geographic name as entry element Yakın Doğu Üniversitesi Makale

a Topical term or geographic name as entry element Asthma

a Topical term or geographic name as entry element Anti-IgE

a Topical term or geographic name as entry element Omalizumab

g Relationship information 2014.

a Main entry heading Immunol 2(2): 1-3.

u Uniform Resource Identifier http://library.neu.edu.tr:2048/login?url=http://dx.doi.org/10.15226/soji/2/2/00116